A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes. Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.

Key facts

Study ID

NCT06699329

Run by

Merck Sharp & Dohme LLC

People needed

38

Starts

2024-01-22

Expected to finish

2024-05-24

Last updated by the study team

2024-11-21

Who can join

Age: 19 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
• Medically healthy with no clinically significant medical history

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• History of gastrointestinal disease which may affect food and drug absorption, or has had a gastric bypass or similar surgery
• History of cancer

Where it is running

• Celerion (Site 0001) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.